Overview

A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants

Status:
Completed
Trial end date:
2018-06-12
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the bioavailability, safety and tolerability of risankizumab following subcutaneous injections in healthy male participants.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Treatments:
Antibodies, Monoclonal